

S3 Table. Patient characteristics according to adjuvant radiotherapy

	Adjuvant radiation therapy (-)	Adjuvant radiation therapy (+)	p-value
No. of patients	157	52	
Age, median (range, yr)	64.0 (32-102)	60 (30-86)	0.098
ECOG			0.925
0	58 (36.9)	18 (34.6)	
1	69 (43.9)	24 (46.2)	
2	1 (0.6)	0	
Not assessed	29 (18.5)	10 (19.2)	
Laterality			0.550
Unilateral, right	74 (47.1)	24 (46.2)	
Unilateral, left	72 (45.9)	27 (51.9)	
Bilateral	1 (0.6)	0	
Not assessed	10 (6.4)	1 (1.9)	
Multiplicity			0.012
No	142 (90.4)	43 (82.7)	
Yes	3 (1.9)	6 (11.5)	
Not assessed	12 (7.6)	3 (5.8)	
Histology			0.158
Invasive ductal carcinoma	128 (81.5)	42 (80.8)	
Mucinous carcinoma	7 (4.5)	2 (3.8)	
Papillary carcinoma	11 (7.0)	2 (3.8)	
Cribriform carcinoma	1 (0.6)	1 (1.9)	
Sarcoma	2 (1.3)	0	
Other	4 (2.5)	0	
Carcinoma	0	2 (3.8)	
Not assessed	4 (2.5)	3 (5.8)	
Grade			0.021
Well	33 (21.0)	3 (5.8)	
Moderate	62 (39.5)	30 (57.7)	
Poor	20 (12.7)	9 (17.3)	
Not assessed	42 (26.8)	10 (19.2)	
Stage			< 0.001
I	60 (38.2)	9 (17.3)	
II	79 (50.3)	15 (28.8)	
III	11 (7.0)	26 (50)	
Not assessed	7 (4.5)	2 (3.8)	
T category			0.346
Tis	1 (0.6)	1 (1.9)	
T1	86 (54.8)	23 (44.2)	
T2	62 (39.5)	22 (42.3)	
T3	2 (1.3)	3 (5.8)	
T4	1 (0.6)	1 (1.9)	
Not assessed	5 (3.2)	2 (3.8)	
N category			< 0.001
N0	91 (58.0)	13 (25.0)	
N1	42 (26.8)	12 (23.1)	
N2	6 (3.8)	12 (23.1)	

N3	5 (3.2)	11 (21.2)	
Not assessed	13 (8.3)	4 (7.7)	
Lymphatic invasion			0.030
No	78 (49.7)	15 (28.8)	
Yes	44 (28.0)	22 (42.3)	
Not assessed	35 (22.3)	15 (28.8)	
Vascular invasion			0.354
No	91 (58.0)	25 (48.1)	
Yes	29 (18.5)	14 (26.9)	
Not assessed	37 (23.6)	13 (25.0)	
Perineural invasion			0.487
No	87 (55.4)	24 (46.2)	
Yes	9 (5.7)	3 (5.8)	
Not assessed	61 (38.9)	25 (48.1)	
ER			0.484
Negative	10 (6.4)	2 (3.8)	
Positive	135 (86.0)	48 (92.3)	
Not assessed	12 (7.6)	2 (3.8)	
PR			0.892
Negative	25 (15.9)	8 (15.4)	
Positive	120 (76.4)	41 (78.8)	
Not assessed	12 (7.6)	3 (5.8)	
HER2			0.270
Negative	72 (45.9)	19 (36.5)	
1+	28 (17.8)	12 (23.1)	
2+	22 (14.0)	13 (25.0)	
3+	15 (9.6)	4 (7.7)	
Not assessed	20 (12.7)	4 (7.7)	
Ki-67, median (range)	15.0 (2.0-70.0)	18.1 (2.0-80.0)	0.749
Classification			0.653
HR (+)	117 (74.5)	43 (82.7)	
HER2 (+)	20 (12.7)	5 (9.6)	
TNBC	8 (5.1)	2 (3.8)	
Not assessed	12 (7.6)	2 (3.8)	
Subtype			0.294
Luminal A	40 (25.5)	19 (36.5)	
Luminal B	27 (17.2)	13 (25.0)	
HER2 positive	20 (12.8)	5 (9.6)	
TNBC	8 (5.1)	2 (3.8)	
Not assessed	62 (39.5)	13 (25.0)	
Operation			0.957
MRM	115 (73.2)	40 (76.9)	
Total mastectomy	36 (22.9)	5 (9.6)	
BCS	5 (3.2)	5 (9.6)	
Node excision	1 (0.6)	2 (3.8)	
LN dissection			0.023
ALND (axillary LN dissection)	89 (57.1)	39 (75.0)	
SLNB (sentinal LN Bx.)	47 (30.1)	5 (9.6)	
Not done	11 (7.1)	3 (5.8)	

Not assessed	9 (5.8)	5 (9.6)	
Neoadjuvant chemotherapy			0.004
No	155 (98.7)	46 (88.5)	
Yes	2 (1.3)	6 (11.5)	
Adjuvant chemotherapy			0.004
No	87 (55.4)	16 (30.8)	
Yes	68 (43.3)	35 (67.3)	
Not assessed	2 (1.3)	1 (1.9)	
Adjuvant endocrine therapy			0.014
No	21 (15.0)	1 (2.1)	
Yes	118 (84.3)	45 (93.8)	
Not assessed	1 (0.7)	2 (4.2)	

Values are presented as number (%) unless otherwise indicated. ALND, axillary lymph node dissection; BCS, breast conserving surgery; Bx, biopsy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; MRM, modified radical mastectomy; PR, progesterone receptor; SLNB, sentinel lymph node biopsy; TNBC, triple-negative breast cancer.